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BACKGROUND:We evaluated both estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)
status on disseminated tumor cells (DTCs) in the bone marrow of 54 patients with early breast cancer and
compared these with the corresponding primary tumor (PT). MATERIALS AND METHODS: Bone marrow aspirates
were obtained at the time of first surgery, and ER and HER2 status on DTCs was assessed simultaneously by
immunocytochemistry using a triple fluorescence staining method. RESULTS: The median number of DTCs was 13
(range 1-95). The concordance rate between ER status on DTC and PT was 74%. Patients with an ER-positive PT
were significantly more likely to have at least one ER-positive DTC (34 out of 42) than patients with an ER-negative
PT (6 out of 12; P = .031). Thirty-nine (93%) of the 42 patients with ER-positive PT had at least one ER-negative
DTC. The concordance rate between HER2 status on DTC and PT was 52%. The probability of having at least one
HER2-positive DTC was not related to the HER2 status of the PT (P = 0.56). Twenty-two (46%) of the 48 patients
with a HER2-negative PT had at least one HER2-positive DTC. All the six patients with a HER2-positive PT had at
least one HER2-negative DTC. CONCLUSION: Taken together, our study confirms that ER and/or HER2 status may
differ between DTC and PT. This discordance could be important for patients lacking ER or HER2 expression on
the PT but showing ER-positive or HER2-positive DTC because they might benefit from an endocrine and/or HER2-
targeted therapy.
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Metastases are the leading cause of death in breast cancer (BC). The
exact mechanism of metastasis development is still not well
understood [1], but it seems that the formation of micrometastasis
in the bone marrow (BM) may be one of the key events [2]. Different
recent studies reported that 15% to 38% of patients with early breast
cancer (EBC) are positive for disseminated tumor cells (DTCs) in the
BM as determined by immunocytochemistry [3–8]. In a pooled
analysis of 4703 patients with EBC and a follow-up of 10 years, the
presence of DTCs in the BM at the time of first diagnosis has been
shown to be an independent prognostic factor with respect to poor
disease-free survival (DFS) and overall survival (OS) [4]. In addition,
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persist in a dormant state for years [9,10]. Indeed, the persistence
of DTCs after chemotherapy in EBC patients without clinical
manifest metastasis, as well as after neoadjuvant chemotherapy in
patients with locally advanced BC, is predictive for DFS, cancer-
specific survival, and OS [11,12]. However, it is still not known
which circumstances allow these cells to switch to an active mode and
spread out into distant organs to manifest metastases years after the
end of adjuvant therapy.
Therefore, one of the key issues in BC research is to phenotype and
characterize DTCs to identify patients at higher risk of relapse and to
select them for secondary adjuvant anticancer therapy (such as
endocrine or targeted therapy). Given that the estrogen receptor (ER)
and HER2 status of the primary tumor (PT) is an essential factor
influencing treatment decisions, we focused our work on the
determination of ER and HER2 status on DTCs as compared
with the PT. It is known that both hormone receptor and HER2
status may change during the course of disease and lead to a different
expression profile of metastases as compared with the PT [13,14].
Previous data show that both ER status [15] and HER2 status [16]
on DTCs may differ compared with the PT; thus, DTCs (which
are thought to be precursor cells of manifest metastases) could serve
as early predictors of such phenotype switching between PT
and metastases.
Our retrospective pilot study of 54 patients with EBC focused on
simultaneously determining ER and HER2 protein expressions on
individual DTC [defined as cytokeratin (CK)-positive cells] with an
easy-to-use triple fluorescence staining method and to compare them
to the corresponding PT.
Materials and Methods
Patients
All patients were treated at the Department of Obstetrics and
Gynecology, Ludwig Maximilian University (Munich, Germany),
between 2006 and 2009. The BM aspiration was performed during
initial BC surgery in general anesthesia from the anterior iliac crest.
Informed consent was obtained from all patients. The study was
conducted in accordance with the ethical principles stated in the most
recent version of the Declaration of Helsinki or the applicable
guidelines of the International Conference on Harmonization Good
Clinical Practice Guideline 1998, whichever represented the greater
protection of the individual. It was approved by the ethical committee
of the Ludwig Maximilian University (Project Number 007/02).
Patients were eligible if they had invasive BC (stages pT1-4, pN0-3,
and M0), no other malignant disease during the last 5 years, and no
neoadjuvant therapy before surgery. The tumor node metastasis
classification according to the revised American Joint Committee on
Cancer was used to categorize the tumor stage at primary diagnosis
[17]. Only patients with detection of CK-positive cells (DTC+)
and known ER and HER2 status of the PT (n = 54) were selected for
this analysis.
Determination of the Phenotype of the PT
The phenotype of the PT was routinely evaluated by immunohis-
tochemical staining and by fluorescence in situ hybridization (FISH)
in HER2-positive cases in the Department of Pathology of the
Ludwig Maximilian University according to the common criteria for
hormone receptor and HER2 determination. ER expression wasdetermined semiquantitatively using the immunoreactive score of
Remmele and Stegner (IRS) (score nuclear staining × score intensity
of ER staining). Tumors having a score of 2 or more were defined as
ER positive [18]. HER2 status of the PT was determined using the
semiquantitative HERCEPTM test (DAKO, Denmark). HER2
expression was categorized from 0 to 3+. 3+ is considered positive.
In case of 2+, HER2 amplification was determined by FISH.
BM Specimens
DTCs, defined as CK-positive cells in BM aspirates, were obtained
in a retrospective series of 54 patients with EBC before the start of
systemic adjuvant therapy. BM aspiration and tumor cell isolation
were performed on the basis of consensus recommendations [19]. In
short, 5 ml of BM was extracted, collected in EDTA-treated tubes,
washed in Hank’s salt solution (Biochrom, Germany, 175g for 10
minutes at 4°C), and processed within 24 hours. Ficoll density
gradient centrifugation with a density of 1.077 g/ml (Biochrom,
Germany, 1105g for 20 minutes at 4°C) was used to enrich
mononucleated cells and to separate them from other BM cells.
Subsequently, the interphase layer containing mononucleated cells
(including tumor cells) was washed in PBS (535g for 10 minutes at
4°C), and a cell count was performed using Malassez cell counting
chambers. A total of 106 cells were spun down at 150g for 5 minutes
at room temperature onto each glass slide. The cytospins were
air-dried at room temperature overnight. For storage, they were
frozen at −80°C until further use and staining (within 5 years).
Triple Fluorescent Staining of CK, ER, and HER2
The triple fluorescent staining of cytospins to detect tumor cells
and determine simultaneously their ER and HER2 status was
performed as described in detail before [20]. In short, cytospins were
thawed at room temperature and immediately fixed using 3.7%
neutral buffered formalin in PBS (Fischer, Saarbrücken, Germany).
Subsequently, these were permeabilized for 2 minutes in cold
(−20°C) methanol (Sigma-Aldrich, Steinheim, Germany), washed in
PBS, and incubated for 15 minutes in Ultra V Blocking medium
(Thermo Scientific, Fremont, CA) to reduce background signals.
Cells were then first incubated for 45 minutes with a rabbit
monoclonal anti-human ER antibody (dilution 1/100, clone sp-1;
Lab Vision, Fremont, CA) and after washing again incubated for 30
minutes with a goat anti-rabbit IgGFab fragment labeled with Cy3
(dilution 1/500, Jackson ImmunoResearch). After another washing
step, cells were incubated for 45 minutes with a rabbit polyclonal
anti-human HER2 antibody (dilution 1/100, A0485; Dako,
Glostrup, Denmark) and with the A45 B/B3 mouse anti-human
CK antibody (dilution 1/200, Micromet, Munich, Germany). This is
a purified monoclonal pan-CK antibody, which reacts with common
epitopes on several CKs including CK8, CK18, and CK19. After
washing, the slides were incubated for 30 minutes with a goat
anti-rabbit IgG labeled with Coumarin-AMCA (dilution 1/200,
Jackson ImmunoResearch) to determine HER2 and a goat
anti-mouse IgG labeled with DyLight488 (dilution 1/200, Jackson
ImmunoResearch) to detect CK. After a final washing step (PBS) and
drying at room temperature, the slides were mounted with Kaiser’s
glycerol gelatin (Merck, Darmstadt, Germany).
Cell Culture and Cytospin Preparation
Regarding the human breast adenocarcinoma cell lines, MCF-7
(ATCC HTP-22) was obtained from the European Collection of Cell
Table 1. Patient and PT Characteristics (n = 54)
Menopausal status Premenopausal 15 (27.8%)
Postmenopausal 39 (72.2%)
pT pT1 29 (53.7%)
pT2 18 (33.3%)
pT3 7 (13.0%)
pN pN0 34 (63.0%)
pN+ 18 (33.3%)
n/a 2 (3.7%)
Histological grading G1 5 (9.3%)
G2 31 (57.4%)
G3 18 (33.3%)
Histological type Ductal 40 (74.1%)
Lobular 10 (18.5%)
Other 4 (7.4%)
ER status Negative 12 (22.2%)
Positive 42 (77.8%)
PR status Negative 20 (37.0%)
Positive 34 (63.0%)
HER2 status Negative 48 (88.9%)
Positive 6 (11.1%)
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line was from the American Type Culture Collection (Rockville,
USA). Cryopreservation of cell cultures ranged from passage 1 to 10.
Cells were expanded up to a maximum of 20 passages. Cells were
grown routinely in Dulbecco’s modified Eagle’s medium (Biochrom,
Berlin, Germany) supplemented with 10% fetal bovine serum (PAA,
Pasching, Austria).
For cytospin preparation, trypsinized cells were centrifuged (700g,
10 minutes, 4°C) and resuspended in PBS (Biochrom, Berlin,
Germany). Then, 106 cells were spread on each cytospin and
centrifuged (45g, 5 minutes, room temperature). Cytospins were
allowed to dry overnight at room temperature and then stored at
−80°C.
Positive and Negative Control
Control cytospins with CK- and ERα-positive MCF-7 cells as well
as CK- and HER2-positive SK-BR-3 cells were prepared, stored, and
fixed in the same way to guarantee that ERα negativity or HER2
negativity of a patient's sample was not due to a technical failure.
MCF-7 cells were used as positive control for ERα and CK staining
and as negative control for HER2. Inversely, SK-BR-3 cells were used
as positive control for HER2 and CK staining and as negative control
for ERα. One MCF-7 and one SK-BR-3 control slides were
systematically evaluated in each batch of patient samples [20].
Cell Detection
Two cytospins (2 × 106 cells) per patient were analyzed. Each
slide was inspected by at least two independent investigators and
by four in doubtful cases within a maximum of 48 hours after
the labeling procedure. The manual analysis was done using
a computerized fluorescence microscope Axioskop (Carl Zeiss
Micro Imaging GmbH) for phase and fluorescence with ×10
and ×40 magnifications. Each observed DTC was documented
with at least one picture with an AxioCam MR camera and an
AxioVision software to capture, analyze, and save high-resolution
images for the three fluorescence channels (Carl Zeiss Microscopy,
Göttingen, Germany).
For identification of DTCs by immunofluorescence, we followed
the consensus recommendations for standardized tumor cell detection
[19], and for HER2-positive DTCs, we followed the criteria already
defined by Solomayer et al. [16]. In general, the cells showed a high
nucleus/cytoplasm ratio. CK positivity was defined as the ring-like
appearance (green, membrane and cytoplasm staining in periphery)
and HER2 overexpression as completely positive membrane staining
(blue, moderate or strong). Criteria for ER positivity were a specific
staining of the nucleus with a low background, a strong nuclear, and
no cytoplasmic or peripheral staining (red).
Statistical Analysis
A patient was classified as having a positive HER2 or ER status of
DTCs if at least one HER2-positive or at least one ER-positive DTC
was detected. Associations between HER2 status or ER status of
DTCs and patient PT characteristics were analyzed using chi-square
tests or Fisher's exact tests. The association between the ER status of
DTCs (no versus at least one ER-positive DTC) and the IRS of the
PT was investigated with the Cochran-Armitage test for trend. All
statistical analyses were performed with IBM SPSS Statistics, version
19, and all P values reported are two-sided with P values below .05
being considered as statistically significant.Results
Patients
Patients and PT characteristics are summarized in Table 1. The
mean age was 59.5 years (range 32-85 years). The majority of the 54
patients was postmenopausal and had a ductal invasive tumor.
Fifty-seven percent showed an intermediate grading (G2), and 63%
had no lymph node involvement. Most of the PTs in the patient
population were rather small, with 54% pT1 tumors. Forty-two
(78%) patients were diagnosed as ER positive, 6 (11%) were classified
as HER2 positive, and 10 patients were classified as triple negative
[i.e., negative for ER, progesterone receptor (PR) and HER2].
Enumeration and ER and HER2 Status Determination of the
DTCs
Using the MCF-7 and SK-BR-3 control cells, we observed that all
54 patients exhibited at least one CK-positive DTC (Figure 1).
Overall, 1082 DTCs were detected in the 54 samples, and the median
number of DTCs detected per sample was 13 (range 1-95) DTCs.
Figure 2A shows the frequency distribution of the number of DTCs
detected in the samples from the 54 patients, illustrating that for most
patients only a small number of DTCs were detected. The frequency
distribution of the DTCs with regard to their ER and HER2 status is
presented in Figure 2B: Of the 1082 DTCs detected, 38 (3.5%) were
ER positive/HER2 positive, 142 (13%) were ER positive/HER2
negative, 43 (4.0%) were ER negative/HER2 positive, and 859
(79%) were ER negative/HER2 negative.
The patient distribution with regard to the presence of ER- and/or
HER2-positive DTCs was as follows (Figure 2C): 10 (19%) patients
had only ER-negative/HER2-negative DTCs. At least one ER-posi-
tive DTC was detected in 40 (74%) patients, at least one
HER2-positive DTC was detected in 24 (44%) patients, and 14
(26%) patients had at least one ER-positive/HER2-positive DTC.
Overall, 93% of the patients (n = 50) had at least one ER-negative/
HER2-negative DTC, and for these 50 patients, ER-negative/
HER2-negative DTCs represent on average 80% (range 40%-100%)
of all DTCs detected.
Association with Clinicopathological Factors
There was no association between the HER2 status of DTCs (i.e.,
the presence of at least one HER2-positive DTC) and any of the
Figure 1. ER and HER2 status determination in control cells and DTCs. Phase, CK, ER, and HER2 staining for an ER-positive control (cell
line MCF-7), a HER2-positive control (cell line SK-Br-3), and DTCs with four different subtypes (ER negative/HER2 negative, ER positive/
HER2 negative, ER negative/HER2 positive, ER positive/HER2 positive). Arrows highlight the ER and HER2 staining: ER with specific
staining of the nucleus with a low background, a strong nuclear, and no cytoplasmic or peripheral staining (red); HER2 overexpression as
completely positive moderate or strong membrane staining (blue). The triple fluorescence labeling of CK, ER, and HER2 was performed
on 106 cells, and phase analysis was performed in parallel. Magnification 40×. Scale bar: 10 μm.
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contrast, the ER status of DTCs was significantly associated with the
ER status of the PT (see Table 2 and below), whereas there was no
association with any of the other clinicopathological factors
(chi-square test, all P N .05; Table 2).
Comparison of ER and HER2 Expression between PT
and DTCs
The concordance rate between the ER status of DTCs and PT was
74% (Table 3). Patients with ER-positive PT were significantly more
likely to have at least one ER-positive DTC (34 out of 42) than
patients with ER-negative PT (6 out of 12; chi-square test, χ2 = 4.66,
P = .031; Table 3). Furthermore, 39 (93%) of the 42 patients with
ER-positive PT and all of the 12 patients (100%) with ER-negative
PT DTCs had at least one ER-negative DTC (not shown in Table 3).
The ER status of DTCs (i.e., the probability of having at least one
ER-positive DTC) was not associated with the IRS of the PT
(Cochran-Armitage test for trend, P = .208).
The concordance rate between HER2 status of DTCs and PT was
52% (Table 4). The probability of having at least one HER2-positive
DTC was not significantly related to the HER2 status of the PT
(chi-square test, χ2 = 0.34, P = .56). Of the 48 patients with a
HER2-negative PT, 22 had at least one HER2-positive DTC, and of
the 6 patients with a HER2-positive PT, 2 had at least one
HER2-positive DTC (Table 4). Forty-six of the 48 patients with a
HER2-negative PT and all of the 6 patients with a HER2-positive PThad at least one HER2-negative DTC. Remarkably, four of the six
patients with HER2-positive PT had HER2-negative DTCs only
(not shown in Table 4).
Heterogeneity of ER and HER2 Combined Expressions of DTCs
The heterogeneity of the combined ER/HER2 status of DTCs and
the association with the ER/HER2 status of the PT are shown in
Table 5. The ER/HER2 status of DTCs of a patient was regarded as
heterogeneous if the DTCs detected in the BM samples of a patient
varied with respect to the ER/HER2 status (there are four different
ER/HER2 profiles: ER negative/HER2 negative, ER positive/HER2
negative, ER negative/HER2 positive, ER positive/HER2 positive). A
heterogeneous ER/HER2 status on DTCs was found in 40 (83%) of
the 48 patients with more than one DTC. Twenty-two (46%) of
these patients had DTCs with two different ER/HER2 profiles, 8
(17%) patients had DTCs with three different ER/HER2 profiles,
and 10 (21%) patients had DTCs with all four possible ER/HER2
profiles. Seven out of the eight patients with more than one DTC and
no heterogeneous ER and HER2 expression (i.e., all DTCs had the
same ER/HER2 profile) had exclusively ER-negative/HER2-negative
DTCs (range 3-31 DTCs), whereas there was one patient with two
ER-positive/HER2-negative DTCs.
Seven out of 10 patients with a triple-negative PT had at least 1
DTC positive for ER, HER2, or both. On the other hand, 9 out of
the 10 patients with a triple-negative PT also had at least 1 DTC
expressing neither ER nor HER2 (Table 5).
Figure 2. Distribution of DTCs (n = 1082). (A) Number of DTCs
detected per patient (n = 54 patients). (B) Number of DTCs
according to their ER/HER2 status. (C) Number of patients
according to the ER/HER2 status of their DTCs.
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In our retrospective study, including 54 patients with EBC and
evidence of DTCs in BM, we detected a total of 1082 DTCs, with
17.5% of the DTCs being positive for ER, 7.5% of the DTCs
positive for HER2 and 3.5% of the DTCs expressing both ER and
HER2 simultaneously. DTCs showing heterogeneity with regard to
their combined ER/HER2 status were observed in 83% of patients
with more than one DTC. The concordance rate between DTCs and
PT regarding ER expression was 74%, whereas the concordance rate
for HER2 expression was only 52%. Patients with an ER-positive PT
were significantly more likely to have at least one ER-positive DTC
compared with patients with an ER-negative PT, whereas the
probability of having at least one HER2-positive DTC was not
significantly related to the HER2 status of the PT.The method of simultaneous determination of ER and HER2
expression on tumor cells has been established in our laboratory and
was previously evaluated in a study focusing on ER and HER2 status
of circulating tumor cells (CTCs) in patients with metastatic BC [20].
The simultaneous determination of ER and HER2 on a single cell
with this easy-to-use staining method has several advantages with
respect to clinical utility, time, and money and may provide new
insights in tumor biology. Furthermore, it may advance DTC
detection and therefore improve patient care. Our study is a rather
small retrospective study (n = 54) including only patients with
evidence of DTCs, which might bias our results. However, to the best
of our knowledge, this is the first study that determined ER and
HER2 protein status on the same DTCs at the same time. Because of
technical reasons, only two important markers (ER and HER2) of BC
were analyzed, whereas other potentially informative markers, such as
PR, could not be evaluated. We focused on ER as a crucial endocrine
marker and HER2 as an essential marker for additional antibody
treatment. Further development of the method could extend the
spectrum of detectable markers and provide additional information
on the phenotype of DTCs. There are, however, several studies that
investigated either ER or HER2 expression on DTCs. In a study
involving 107 patients with DTCs in the BM, Fehm et al. (2008a)
confirmed the findings of some previous smaller studies that the ER
status on minimal residual disease does not necessarily mirror the ER
status of the PT [15]. In addition, Fehm et al. (2008a) reported that
the majority of DTCs tended to be ER negative, which is in
accordance with our finding that 902 out of 1082 DTCs were ER
negative. However, the concordance rate of the ER status of DTCs
compared with the PT in the study by Fehm et al. (2008a) was only
28% and thus considerably lower than the 74% concordance rate
observed in our study. Furthermore, the probability of having
ER-positive DTCs was not related to the ER status of the PT, which
is in contrast to our findings.
Similar to the ER status results, the majority of studies exploring
the HER2 status describe some discordance between the HER2 status
on DTCs and the corresponding PT. The concordance rate of 52%
found in our study is at the lower end of HER2 concordance rates as
reported in the previous studies, which ranged from 51% to 77%
[3,6,16,21–23]. An even larger variability seems to exist with respect
to the proportion of patients with a HER2-negative PT that have
HER2-positive DTCs. Solomayer et al. compared the HER2 status
between DTCs and corresponding PT in 46 patients and reported
that HER2-positive DTCs were detected in 60% of patients with a
HER2-negative PT [16] compared with 51% found in the study by
Hartkopf et al. [21] and 46% as observed in our study.
Krishnamurthy et al. investigated HER2 gene amplification on
DTCs using FISH and showed a discordance rate of HER2 gene
amplification between DTCs and PT of 28%, with only 21% of
patients with HER2-negative PT having at least one HER2-positive
DTC [23]. An even lower proportion was reported by Becker et al.
who detected HER2-positive DTCs in 15% to 21% of patients using
immunocytochemistry or reverse transcription polymerase chain
reaction and observed that only 13% of patients with a HER2-
negative PT hadHER2-positive DTCs [22]. Clearly, more research and
standardization of detection methods are needed to evaluate factors
responsible for the large discrepancies with regard to the proportion of
patients with a HER2-negative PT that have HER2-positive DTCs.
DTCs and even HER2 divergence on DTCs [6] may persist after
(neo-)adjuvant chemotherapy [9,24,25]. Both the HER2
Table 2. Association of Patient and PT Characteristics with HER2 Status and ER Status of DTCs Detected in BM Samples of 54 BC Patients
HER2 Status of DTCs ER Status of DTCs
At Least One HER2-Positive
DTC (n = 24)
No HER2-Positive
DTC (n = 30)
P Value At Least One ER-Positive
DTC (n = 40)
No ER-Positive
DTC (n = 14)
P Value
Menopausal status Premenopausal 7 8 .839 † 11 4 1.000
Postmenopausal 17 22 29 10
pT pT1 13 16 .996 † 24 5 .254 †
pT2 8 10 11 7
pT3 3 4 5 2
pN pN0 15 19 .982 † 27 7 .197
pN+ 8 10 11 7
n/a 1 1 2 0
Histological grading G1 1 4 .486 † 5 0 .059 †
G2 14 17 25 6
G3 9 9 10 8
Histological type Ductal 17 23 .889 † 27 13 .164 †
Lobular 5 5 9 1
Other 2 2 4 0
ER status Negative 5 7 .826 † 6 6 .031 †
Positive 19 23 34 8
PR status Negative 8 12 .614 † 12 8 .070 †
Positive 16 18 28 6
HER2 status Negative 22 26 .682 36 12 .643
Positive 2 4 4 2
Exact Fisher test.
† Chi-square test (without unknowns).
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persistence of DTCs after systemic therapy are known independent
prognostic factors with respect to poor outcome [11,12,21,26]. For
example, Hartkopf et al. [21] reported that mean DFS was
significantly shorter in patients with EBC and HER2-positive
DTCs compared with patients with only HER2-negative DTCs (n
= 151; as determined at the time of first surgery). They showed by
using multivariate analysis that the HER2 status on DTCs was an
independent predictor of DFS. One current hypothesis is that the
spread of tumor cells occurs early in BC history [27] and that these
cells may persist in a dormant, nonproliferating state for years [10]. In
addition, these cells may demonstrate stem cell characteristics [28]
and acquire a more aggressive phenotype during metastatic latency
within the BM microenvironment [29]. In line with this, our study
shows that 93% of patients with ER-positive PT have ER-negative
DTCs and even 46% with HER2-negative PT show HER2-positive
DTCs. One possible explanation for the observed discordances is the
clonal heterogeneity of the PT, which might result in the
dissemination of cells with different phenotype. An additional reason
might be that ER-negative and HER2-positive DTCs disseminate
more frequently due to their more aggressive phenotype. The fact that
patients with ER-positive PT develop ER-negative metastatic lesions
[13] and that patients with HER2-negative PT may become HER2able 3. Association between the ER Status of the PT (ER Negative, ER Positive) and the
R Status of DTCs (Only ER-Negative DTCs, At Least One ER-Positive DTC) in 54 Primary
C Patients
ER Status DTCs Total (%)
Only ER-Negative
DTCs (%)
At Least One ER-Positive
DTC (%)
umor ER negative (%) 6 (11) 6 (11) 12 (22)
ER positive (%) 8 (15) 34 (63) 42 (78)
Total (%) 14 (26) 40 (74) 54 (100)
concordant ER status between PT and DTCs was found in 40 of the 54 (74%) patients.
P = .031 (chi-square test).
Table 4. Association between the HER2 Status of the PT (HER2 Negative, HER2 Positive) and th
HER2 Status of DTCs (Only HER2-Negative DTCs, At Least One HER2-Positive DTC) in 54
Primary BC Patients
HER2 Status DTCs Total (%
Only HER2-Negative
DTCs (%)
At Least One HER2-Positive
DTC (%)
Tumor HER2 negative
(%)
26 (48) 22 (41) 48 (89)
HER2 positive
(%)
4 (7) 2 (4) 6 (11)
Total (%) 30 (55) 24 (45) 54 (100)
A concordant HER2 status between PT and DTCs was found in 28 of the 54 (52%) patients.
P = .56 (chi-square test).T
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Apositive [14] during the course of disease is in accordance with this
hypothesis and further emphasizes the need of reassessing the current
phenotype. For this purpose, DTCs could serve as early predictors of
divergences of the phenotype between PT and potential metastases.
Bisphosphonates and trastuzumab have been used to eliminate
DTCs and HER2-positive DTCs persisting after adjuvant therapy,
respectively [30–32]. Still, in our study, 79% of the DTCs are
negative for both ER and HER2, which may also explain some of the
unexpected failures of endocrine or HER2-targeted therapy and
define a patient population not suitable for secondary endocrine or
HER2-targeted therapy. This underlines the need to develop new
targeted agents including stem cell activity. Vincent-Salomon and
colleagues suggest that the next step to determine whether eradication
of DTCs in the BM after systemic therapy results in longer survival
must be large-scale prospective clinical trials [33]. The presence of
tumor cells in the BM identifies a population of patients at high risk
for recurrence [4,7,12,34]. However, because of issues related to
testing, reporting, and lack of standardized protocols, BM aspiration
is still not a standard of care and currently not recommended for all
patients with BC [7,19,23]. Nevertheless, the increasing interest in
the examination of BM as a tissue source for the study ofe
)
Table 5. Combined ER/HER2 Status of DTCs and Association with the ER/HER2 Status of the PT
DTCs with One
ER/HER2 Profile
DTCs with Two
ER/HER2 Profiles
DTCs with
Three ER/
HER2 Profiles
DTCs with Four
ER/HER2 Profiles
ER/HER2 status of DTCs ER+/HER2− + + + + +
ER+/HER2+ + + + +
ER−/HER2− + + + + + + +
ER−/HER2+ + + + +
ER/HER2 status of PT ER+/HER2−(n = 38) 2 1 5 13 1 2 2 4 8
ER+/HER2+ (n = 4) 1 2 1
ER−/HER2− (n = 10) 3 1 3 1 1 1
ER−/HER2+ (n = 2) 1 1
Total (n = 54) 2 1 10 1 18 1 3 2 6 10
Shown are the numbers of patients with a given ER/HER2 status of the PT that have DTCs with ER/HER2 profiles as indicated by the “+” signs above. For example, there were five patients with an
ER-positive/HER2-negative PT that had only ER-negative/HER2-negative DTCs, and there were three patients with an ER-negative/HER2-negative PT that had both ER-positive/HER2-negative and
ER-negative/HER2-negative DTCs.
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will lead to a better understanding of the biology of metastatic disease
[23]. The enumeration and detection of DTCs according to
standardized protocols and subsequent phenotypic and molecular
characterization of these cells may increase early detection, improve
prognostic accuracy, and contribute to an enhanced identification of
patients which may benefit from additional systemic anticancer
therapy. Further advances in the design of personalized therapies may
therefore lead to the stratification of patients to secondary adjuvant
therapies. These therapies could include secondary endocrine therapy
in case of hormone receptor–negative PT but ER-positive DTCs, or
HER2-targeted therapy in patients with HER2-negative BC but
evidence of HER2-positive DTCs. Patients might benefit from
individualized and personalized treatment options; however, treat-
ment plans and decision making will get even more complex and time
consuming, and be a source of mistakes. On the other hand, DTCs
lacking ER or HER2 in patients with hormone receptor–positive or
HER2-positive PT might explain failures of endocrine or HER2-
targeted therapies and open the way for alternative, potentially more
appropriate systemic treatments options.
The question of whether a single DTC is representative for the
reaction of all occult tumor cells and drug response of the
corresponding tumor tissue may only be answered by prospective
clinical trials. Furthermore, the suitability of DTC as a surrogate
marker to monitor systemic therapy remains to be revealed in future
studies [35]. For example, the efficacy of HER2-targeted therapy
could be assessed in a clinical trial by sequential detection of
HER2-positive DTCs (before and after treatment) [36]. Ongoing
trials, for example, focus on personalized targeted therapies according
to the phenotype of CTCs in patients with HER2-negative metastatic
BC (DETECT III and IV) or on secondary adjuvant HER2-targeted
therapy in HER2-negative EBC with persisting CTCs after
(neo-)adjuvant chemotherapy.
Conclusion
Differences in ER and HER2 expression on potentially metastase-
s-initiating DTCs or metastases compared with the PT are a known
phenomenon in BC and may have clinical implications with respect
to targeted treatment approaches. In our study, we showed a high
degree of discordance regarding ER and HER2 expression between
DTCs and PT by determining both ER and HER2 status
simultaneously on the same cell using a triple fluorescent stainingmethod. The presence of ER-negative or HER2-negative DTCs in
patients with ER-positive or HER2-positive PT might explain
unexpected failures of HER2-targeted or endocrine therapy. The
evaluation of ER and HER2 status on DTCs could be especially
important for patients lacking ER or HER2 expression on the PT, as
patients showing ER-positive or HER2-positive DTCs might benefit
from a secondary endocrine or HER2-targeted therapy. Prospective
randomized trials are needed to evaluate these possibilities.
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